|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
|
FDA Issues Guidance on Hospital Bed Design to Reduce Patient EntrapmentDate: 3/24/2006
Reason: Entrapment can occur when part of a patient's body becomes caught between parts of the bed, such as in the space between the mattress and the side rail. This can cause strangulation and death.
Distribution: Nationwide.
Media Inquiries: The guidance, entitled "Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment" identifies special issues associated with hospital bed systems and provides design recommendations for manufacturers of new hospital beds and suggestions for health care facilities on ways to assess existing beds. The guidance characterizes the body parts at risk for entrapment, identifies the locations of hospital bed openings that are potential entrapment areas, recommends dimensional criteria for new hospital bed systems, provides information about reporting entrapment adverse events, and includes a description of recommended test methods for assessing gaps in hospital bed systems. Key body parts at risk of entrapment are: Head 1.Within the rail FDA has received approximately 691 entrapment reports over a period of 21 years from January 1, 1985 to January 1, 2006 . In these reports, 413 people died, 120 were injured, and 158 were near-miss events with no serious injury as a result of intervention. These entrapment events have occurred in openings within the bed rails, between the bed rails and mattresses, under bed rails, between split rails, and between the bed rails and the head or foot boards. Elderly patients in hospitals and nursing homes, especially those who are frail, confused, restless, or who have uncontrollable body movement, are most vulnerable to entrapment. Entrapments have occurred in a variety of patient care settings, including hospitals, nursing homes, and private homes. Long-term care facilities reported the majority of the entrapments. "While these numbers appear small, we believe they are signals about significant adverse events. Often, adverse events such as these go unreported to the FDA making it likely our counts of these tragic adverse incidents is lower than the number that actually occurs," said Dr. Kessler. The final guidance, "Guidance for Industry and FDA Staff; Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment," is available on FDA's website at: http://www.fda.gov/cdrh/beds/.
Other Drugs / Medicines Recalls and Alerts of InterestDate: 6/12/2008 Reason: Limited lots of Carmeda-coated products were manufactured with heparin found to have been contaminated with oversulfated chondroitin sulfate (OSCS). Distribution: Nationwide Date: 6/16/2008 Reason: Oversized tablets may contain as much as two times the labeled level of active morphine sulfate Distribution: Nationwide Date: 6/12/2008 Reason: Taking AZASAN® instead of SOLODYN® presents a health hazard and safety risk to patients Date: 6/12/2008 Reason: it contained a potentially harmful undeclared ingredient, hydroxyhomosildenafil Distribution: Nationwide Date: 6/12/2008 Reason: Oversized tablets may contain as much as two times the labeled level of active morphine sulfate Date: 6/12/2008 Reason: Limited lots of Atrium heparin-coated Hydraglide Thoracic Catheters were manufactured with heparin found to have been contaminated with oversulfated chondroitin sulfate (OSCS) Distribution: Nationwide |
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.








